A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

Condition:   Episodic Cluster Headache
Interventions:   Drug: Fremanezumab – A;   Drug: Fremanezumab – B;   Drug: Placebo
Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting – verified August 2017
Source: ClinicalTrials.gov Listing of Cluster Headache trials
This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 (Fremanezumab) versus placebo in adult patients for the prevention of ECH.